Sandbox vidit3: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 29: Line 29:
<tr><td>BNP</td><td>center dependent</td></tr>
<tr><td>BNP</td><td>center dependent</td></tr>
<tr><td>RHC</td><td>Q 6 to Q 12 months or clinical deterioration</td></tr>
<tr><td>RHC</td><td>Q 6 to Q 12 months or clinical deterioration</td></tr>
</table>
<table class="wikitable">
<tr class="v-firstrow"><th></th><th></th></tr>
<tr><td></td><td></td></tr>
<tr><td></td><td> </td></tr>
<tr><td></td><td> </td></tr>
<tr><td></td><td></td></tr>
<tr><td></td><td></td></tr>
<tr><td></td><td></td></tr>
<tr><td></td><td></td></tr>
</table>
</table>

Revision as of 17:17, 28 February 2014

DrugAdult dosage
Inhaled Short Acting β Agonists (SABA)
Albuterol/Bitolterol/Pirbuterol
a) Nebulizer solution
b) MDI

♦ 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed or 10-15 mg/hour continuously.
♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed.
Levalbuterol
a) Nebulizer solution
b) MDI

♦ 1.25-2.5 mg every 20 mins for 3 doses, then 1.25-5 mg every 1-4 hours as needed.
♦ 4-8 puffs every 20 mins upto 4 hours, then every 1-4 hours as needed.
Anticholinergics
Ipratropium bromide
a) Nebulizer solution
b) MDI

♦ 0.5 mg every 20 mins for 3 doses, then as needed.
♦ 8 puffs every 20 mins as needed for upto 3 hours.
Ipratropium with albuterol
a) Nebulizer solution (each 3 ml containing 0.5 mg ipratropium and 2.5 mg albuterol)
b) MDI (each puff contains 18 mcg ipratropium and 90 mcg albuterol)

♦ 3 ml every 20 mins for 3 doses, then as needed.
♦ 8 puffs every 20 mins as needed for 3 hours
Systemic corticosteroids
Prednisone/Prednisolone/Methylprednisolone ♦ 40-80 mg/day in 1 or 2 divided doses until peak expiratory flowrate (PEF) reaches 70% of personal best.


Clinical courseUnstable
Physical examination Signs of heart failure
Functional class IV
6MWD Less than 400 m
EchocardiogramRV Enlargement
HemodynamicsRAP high
CI low
BNPElevated/Increasing
TreatmentIntravenous prostacyclin and/or combination treatment
Frequency of evaluation Q 1 to Q 3 months
FC assessment Every clinic visit
6MWT Every clinic visit
Echocardiogram2Q 6 to Q 12 months/center dependent
BNPcenter dependent
RHCQ 6 to Q 12 months or clinical deterioration